Ever since Gilead Sciences began selling its Sovaldi hepatitis C treatment, there has been controversy over the price. State Medicaid directors have struggled to restrict usage. A congressional hearing was held. And at one point, the nationâ€™s biggest pharmacy benefit manager urged companies and health plans to switch to medicines made by rival companies once those drugs are approved.

But the Southeastern Pennsylvania Transportation Authority has decided on a different tack. The transit agency, which serves the greater...